Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.325 CAD | -1.04% | -3.34% | -15.82% |
07/06 | Transcript : HLS Therapeutics Inc. - Shareholder/Analyst Call | |
28/05 | HLS Therapeutics Notes Role of Pharmaceutical Support Programs on Persistence with Clozapine Treatment in Quebec Study | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.82% | 77.19M | |
-1.17% | 24.26B | |
+15.06% | 8.74B | |
+1.71% | 8.21B | |
-31.14% | 6.87B | |
+16.61% | 5.29B | |
+1.92% | 4.13B | |
-9.24% | 3.79B | |
-8.91% | 3.34B | |
+7.27% | 3.19B |
- Stock Market
- Equities
- HLS Stock
- News HLS Therapeutics Inc.
- HLS Therapeutics Brief: John Welborn, Jr. Appointed Chair of the Board, Succeeding Greg Gubitz, who is Retiring; John Hanna Appointed as an independent director